DoMore Diagnostics is proud to welcome leading colorectal cancer researchers and clinicians Dr. Jeanine Roodhart (UMC Utrecht) and Dr. Frank Sinicrope (Mayo Clinic) to its Scientific Advisory Board.

DoMore Diagnostics and Gustave Roussy, Europe’s top-ranked cancer center, are proud to announce a clinical research collaboration.

DoMore Diagnsotics is pleased to announce the appointment of Madeleine Xuyen Ho as our new Product Manager. With a strong market and customer-focused mindset, Madeleine will play a key role in driving DoMore Diagnostics’ Histotype Px product portfolio to clinical implementation and commercial launch.  

The study was conducted by the National Cancer Center Hospital East (Kashiwa, Japan) and the Institute for Cancer Genetics and Informatics, OUS (Oslo, Norway) and included 1082 R0 resected stage II and stage III patients from the CIRCULATE-Japan GALAXY trial, a large-scale prospective observational study.

The granted patent provides important protection of the novel methods underpinning DoMore Diagnostics’ digital biomarkers including the use of histological image analysis to predict patient outcomes.

DoMore Diagnostics and University Medical Centre Utrecht (UMC Utrecht), one of Europe’s top-ranked academic research centers and a pioneer in the adoption of digital pathology, are proud to announce a research collaboration.

DoMore Diagnostics has been awarded the prestigious title of "AI Startup of the Year" by the Norwegian Artificial Intelligence Research Consortium (NORA)

Building on previously published validations in European colorectal cancer patient cohorts, the study was conducted by The Ohio State University Comprehensive Cancer Center (OSUCCC) and supports the clinical applicability of Histotype Px in a U.S. patient cohort.

DoMore Diagnostics has been awarded up to €10 million in grant and equity financing by the EIC Accelerator program to support the company through key milestones leading to commercial launch and scale-up of its digital biomarker Histotype Px® Colorectal.

Histotype Px® Colorectal will be added to Paige’s new AppLab™ Marketplace.

DoMore Diagnostics has been awarded NOK 16 million in public grant funding from The Research Council of Norway for the project “Clinical validation and implementation of the AI-based digital biomarker Histotype Px® to personalize treatment in colorectal cancer”.

Under the agreement, Stavanger University Hospital will validate Histotype Px® Colorectal biomarker in patients from the Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer (ACROBATICC) study and test the clinical utility of the digital biomarker in a group of Norwegian stage II/III colorectal cancer patients.

OSLO and PHILADELPHIA – August 30, 2023 – DoMore Diagnostics, a leader in deep learning precision diagnostics for digital pathology, and Proscia®, a leading provider of digital and computational pathology solutions, have partnered to help pathologists predict outcomes for colorectal cancer (CRC) patients. The collaboration paves the way for integrating artificial intelligence (AI)-powered clinical decision support into routine pathology workflows, unlocking new insights that can guide increasingly precise treatment decisions and ensure patients receive optimal care.